Company

Newlimit, Inc.

Newlimit develops medicines for age-related diseases using epigenetic reprogramming.

About

Newlimit uses machine learning, functional genomics and other methods to study aging and develop treatments. Founded in 2021, the company is based in South San Francisco, US. It raised USD 435 million in series C funding led by Founders Fund in June 2026, at a USD 3.1 billion post-money valuation.

4Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in